The study included 2,900 patients admitted to Wuhan, China-based Huo Shen Shan Hospital during February and March. It showed that COVID-19 patients taking medicine to manage their blood pressure experienced a significantly lower risk of death than patients with hypertension who were not taking medication.
The researchers also pooled prior research to discover that ACE inhibitors and ARBs, specific classes of blood pressure drugs, may be associated with a lower risk of death from COVID-19.
Their evidence comes from observational studies, not randomized trials, but the researchers argue that patients should not chaInge their antihypertensive treatment unless their physician explicitly tells them.
COVID-19 patients have been encouraged to keep taking their prescribed hypertension drugs by the American College of Cardiology, American Heart Association and Heart Failure Society of America, according to CNBC.
More articles on pharmacy:
Pharmacist salaries across the most common work settings
FDA asks 5 drugmakers to recall metformin products
Remdesivir could make billions for Gilead, analyst says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
